Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

The Pattern Of Cytogenetic Aberrations In CML BC Stratified For Treatment

Blood (2013) 122 (21): 2737.

https://doi.org/10.1182/blood.V122.21.2737.2737

Published: 2013

Journal Articles

Congenital dyserythropoietic anemias: molecular insights and diagnostic approach

Achille Iolascon, Hermann Heimpel, Anders Wahlin, Hannah Tamary

Blood (2013) 122 (13): 2162–2166.

https://doi.org/10.1182/blood-2013-05-468223

Published: 2013

Journal Articles

Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

Blood (2012) 120 (21): 67.

https://doi.org/10.1182/blood.V120.21.67.67

Published: 2012

Journal Articles

Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts

Blood (2012) 120 (21): 3748.

https://doi.org/10.1182/blood.V120.21.3748.3748

Published: 2012

Journal Articles

A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene

Bernard Grandchamp, Gilles Hetet, Caroline Kannengiesser, Claire Oudin, Carole Beaumont, Sylvie Rodrigues-Ferreira, Robert Amson, Adam Telerman, Peter Nielsen, Elisabeth Kohne, Christina Balser, Hermann Heimpel

Blood (2011) 118 (25): 6660–6666.

https://doi.org/10.1182/blood-2011-01-329011

Published: 2011

Includes: Supplemental data

Journal Articles

Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients

Blood (2010) 116 (21): 671.

https://doi.org/10.1182/blood.V116.21.671.671

Published: 2010

Journal Articles

Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV

Benjamin Hanfstein, MD, Martin C. Müller, MD, Philipp Erben, MD, Susanne Schnittger, PhD, Susanne Saussele, MD, Armin Leitner, MD, Ulrike Proetel, MD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Hermann Heimpel, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, The German CML-Study Group

Blood (2010) 116 (21): 360.

https://doi.org/10.1182/blood.V116.21.360.360

Published: 2010

Journal Articles

Molecular Analysis of the SEC23B Gene In Patients Affected by Congenital Dyserythropoietic Anemia Type II (CDAII)

Paola Bianchi, PhD, Klaus Schwarz, MD, Elisa Fermo, PhD, Katja Heinrich, MD, Cristina Vercellati, PhD, Anna Paola Maria Luisa Marcello, PhD, Richard van Wijk, PhD, Rob van Zwieten, MD, Laura Banov, MD, Antonella Sau, MD, Walter A. Wuillemin, MD, Stephen Opat, MD, Wilma Barcellini, MD, Hermann Heimpel, MD, Prof., Alberto Zanella, MD

Blood (2010) 116 (21): 4227.

https://doi.org/10.1182/blood.V116.21.4227.4227

Published: 2010

Journal Articles

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

Blood (2009) 114 (22): 862.

https://doi.org/10.1182/blood.V114.22.862.862

Published: 2009

Journal Articles

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Blood (2009) 114 (22): 339.

https://doi.org/10.1182/blood.V114.22.339.339

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies.

Blood (2009) 114 (22): 3281.

https://doi.org/10.1182/blood.V114.22.3281.3281

Published: 2009

Journal Articles

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

Blood (2008) 112 (11): 184.

https://doi.org/10.1182/blood.V112.11.184.184

Published: 2008

Journal Articles

Response: Drug treatment and allografting as first-line therapy in young patients with CML

Rüdiger Hehlmann, Alois Gratwohl, Markus Pfirrmann, Jörg Hasford, Andreas Hochhaus, Dieter K. Hossfeld, Hermann Heimpel

Blood (2007) 110 (13): 4618–4619.

https://doi.org/10.1182/blood-2007-07-103861

Published: 2007

Journal Articles

Activating Mutation of Heme Oxygenase (HO)-1: A Novel Disease Entity Characterized by Microcytic, Hemolytic Anemia, a Defect of Bilirubin Synthesis and Hereditary Hemophagocytic Lymphohistiocytosis.

Johann Greil, MD, Mavi Verga-Falzacappa, Hirokazu Tsukahara, M.D., Wolfgang Behnisch, M.D., Hermann Heimpel, M.D., Marion Schneider, PhD, Gritta Janka, M.D., Maren Claus, PhD, Martina Muckenthaler, PhD, Andreas E. Kulozik, M.D.

Blood (2007) 110 (11): 235.

https://doi.org/10.1182/blood.V110.11.235.235

Published: 2007

Journal Articles

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Blood (2007) 109 (11): 4686–4692.

https://doi.org/10.1182/blood-2006-11-055186

Published: 2007

Includes: Supplemental data

Journal Articles

Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia.

Rudiger Hehlmann, MD, Markus Pfirrmann, MSc, Andreas Hochhaus, MD, Martin C. Müller, MD, Jörg Hasford, MD, Hans-Jochem Kolb, MD, Hermann Heimpel, MD, Dieter K. Hossfeld, MD, Alois Gratwohl, MD, the German CML-Study Group

Blood (2006) 108 (11): 427.

https://doi.org/10.1182/blood.V108.11.427.427

Published: 2006

Journal Articles

In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.

Guntram Buesche, Rudiger Hehlmann, Arnold Ganser, Hartmut Hecker, Andreas Hochhaus, Hermann Heimpel, Barbara Heinze, Claudia Schoch, PD., Dorothea Gadzicki, Martin Mueller, Nils von Neuhoff, Susanne Schnittger, PD., Brigitte Schlegelberger, Bernd Frye, Axel Georgii, Hans Kreipe

Blood (2006) 108 (11): 2195.

https://doi.org/10.1182/blood.V108.11.2195.2195

Published: 2006

Journal Articles

Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation

Hermann Heimpel, Klaus Schwarz, Monika Ebnöther, Jeroen S. Goede, Detlev Heydrich, Torsten Kamp, Lothar Plaumann, Bettina Rath, Jochen Roessler, Otto Schildknecht, Mathias Schmid, Walter Wuillemin, Beate Einsiedler, Rosi Leichtle, Hannah Tamary, Elisabeth Kohne

Blood (2006) 107 (1): 334–340.

https://doi.org/10.1182/blood-2005-01-0421

Published: 2006

Journal Articles

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Guntram Buesche, Ruediger Hehlmann, Arnold Ganser, Hartmut Hecker, Mathias Freund, Hermann Heimpel, Barbara Heinze, Dorothea Gadzicki, Brigitte Schlegelberger, Christa Fonatsch, Bernd Frye, Andreas Tobler, Axel Georgii, Hans H. Kreipe

Blood (2005) 106 (11): 1106.

https://doi.org/10.1182/blood.V106.11.1106.1106

Published: 2005

Journal Articles

Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV.

Ute Berger, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Claudia Schoch, MD, Andreas Reiter, MD, Gerhard Ehninger, MD, Thomas Fischer, MD, Alois Gratwohl, MD, Joerg Hasford, MD, Hermann Heimpel, MD, Dieter K. Hossfeld, MD, Hans-J. Kolb, MD, Stefan Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Andreas Tobler, MD, Ruediger Hehlmann, MD, The German CML-Study Group

Blood (2005) 106 (11): 1083.

https://doi.org/10.1182/blood.V106.11.1083.1083

Published: 2005

NARROW

The Pattern Of Cytogenetic Aberrations In CML BC Stratified For Treatment

Congenital dyserythropoietic anemias: molecular insights and diagnostic approach

Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts

A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene

Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients

Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV

Molecular Analysis of the SEC23B Gene In Patients Affected by Congenital Dyserythropoietic Anemia Type II (CDAII)

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies.

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

Response: Drug treatment and allografting as first-line therapy in young patients with CML

Activating Mutation of Heme Oxygenase (HO)-1: A Novel Disease Entity Characterized by Microcytic, Hemolytic Anemia, a Defect of Bilirubin Synthesis and Hereditary Hemophagocytic Lymphohistiocytosis.

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia.

In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.

Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only